Literature DB >> 11998899

Autoantibody responses in Chinese hepatocellular carcinoma.

Jian-Ying Zhang1, Xiao Wang, Xuan-Xian Peng, Edward K L Chan.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is particularly prevalent in Henan, China. The objective of this study was to analyze the frequency and specificity of autoantibodies associated with HCC in Henan. In the present study, 137 sera from HCC patients, 77 sera from other liver diseases, and 30 sera from normal human individuals were examined for autoantibodies using immunohistochemistry, Western blotting, and immunoprecipitation assays. Autoantibodies were detected in 80 of 137 (58.4%) HCC sera. Antinucleolar antibodies were seen more frequently in HCC compared to other liver diseases (9.5% vs. 1.3%, P < 0.05). Two nucleolar proteins-fibrillarin and NOR-90/ hUBF-were identified as autoantigens. The frequency of autoantibodies in HCC sera with known hepatitis C virus (HCV) infection was significantly higher than that in sera without HCV infection (84.2% vs. 57.7%, P < 0.01). Another interesting finding was that autoantibodies to a 90-kDa cytoplasmic antigen were found in 21% of HCC patients. This is the first report on the frequency and specificity of autoantibodies in sera from Chinese patients with HCC. The data support that autoimmune responses to certain cellular proteins may be a by-product in the transformation to HCC, and further studies of novel targeted autoantigens in Chinese HCC may provide insights into how these proteins might be involved in malignancy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998899     DOI: 10.1023/a:1014483803483

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

1.  Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases.

Authors:  M Seiner; E Klein; G Klein
Journal:  Clin Immunol Immunopathol       Date:  1975-09

Review 2.  Paraneoplastic syndromes affecting the central nervous system.

Authors:  J B Posner; J O Dalmau
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

3.  The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo.

Authors:  R J Buckanovich; R B Darnell
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 4.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

5.  Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma.

Authors:  H Imai; Y Nakano; K Kiyosawa; E M Tan
Journal:  Cancer       Date:  1993-01-01       Impact factor: 6.860

Review 6.  Hepatitis virus-related hepatocarcinogenesis.

Authors:  O Hino; K Kajino
Journal:  Intervirology       Date:  1994       Impact factor: 1.763

7.  Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies.

Authors:  H Imai; R L Ochs; K Kiyosawa; S Furuta; R M Nakamura; E M Tan
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

8.  Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

Authors:  S M Pupa; S Ménard; S Andreola; M I Colnaghi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

9.  A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma.

Authors:  S Hadziyannis; E Tabor; E Kaklamani; A Tzonou; S Stuver; N Tassopoulos; N Mueller; D Trichopoulos
Journal:  Int J Cancer       Date:  1995-03-03       Impact factor: 7.396

10.  New paths in human cancer serology.

Authors:  L J Old; Y T Chen
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more
  8 in total

1.  Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.

Authors:  Kok Sun Looi; Ernesto S Nakayasu; Raquel A de Diaz; Eng M Tan; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2008-08-02       Impact factor: 4.466

2.  Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.

Authors:  Jian-Ying Zhang; Roxanne Megliorino; Xuan-Xian Peng; Eng M Tan; Yao Chen; Edward K L Chan
Journal:  J Hepatol       Date:  2006-09-25       Impact factor: 25.083

Review 3.  Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.

Authors:  Weihong Liu; Bo Peng; Yumin Lu; Weijia Xu; Wei Qian; Jian-Ying Zhang
Journal:  Autoimmun Rev       Date:  2010-12-15       Impact factor: 9.754

Review 4.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

5.  HapMap-based study of CIP2A gene polymorphisms and HCC susceptibility.

Authors:  Yuchun Li; Kaijuan Wang; Liping Dai; Peng Wang; Chunhua Song; Jianxiang Shi; Pengfei Ren; Hua Ye; Jianying Zhang
Journal:  Oncol Lett       Date:  2012-05-23       Impact factor: 2.967

Review 6.  Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma.

Authors:  Jian-Ying Zhang
Journal:  Autoimmun Rev       Date:  2006-10-10       Impact factor: 9.754

7.  Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.

Authors:  Yao Chen; Yusen Zhou; Suimin Qiu; Kaijuan Wang; Siwei Liu; Xuan-Xian Peng; Junfeng Li; Eng M Tan; Jian-Ying Zhang
Journal:  Cancer Lett       Date:  2009-08-15       Impact factor: 8.679

8.  Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC).

Authors:  Liping Dai; Ningjing Lei; Mei Liu; Jian-Ying Zhang
Journal:  Exp Hematol Oncol       Date:  2013-05-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.